Last update 28 Mar 2025

Lenalidomide

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CMIO-LLD
+ [18]
Action
inhibitors, modulators
Mechanism
CK1α inhibitors(casein kinase 1 alpha 1 inhibitors), CRBN modulators(Cereblon modulators), IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Dec 2005),
RegulationOrphan Drug (United States), Priority Review (China), Special Review Project (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H13N3O3
InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N
CAS Registry191732-72-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Large B-cell lymphoma
United States
11 Feb 2025
Marginal Zone B-Cell Lymphoma
United States
28 May 2019
Adult T-Cell Leukemia-Lymphoma
Japan
02 Mar 2017
Chromosome 5q Deletion Syndrome
European Union
14 Jun 2007
Chromosome 5q Deletion Syndrome
Iceland
14 Jun 2007
Chromosome 5q Deletion Syndrome
Liechtenstein
14 Jun 2007
Chromosome 5q Deletion Syndrome
Norway
14 Jun 2007
Follicular Lymphoma
European Union
14 Jun 2007
Follicular Lymphoma
Iceland
14 Jun 2007
Follicular Lymphoma
Liechtenstein
14 Jun 2007
Follicular Lymphoma
Norway
14 Jun 2007
Mantle-Cell Lymphoma
European Union
14 Jun 2007
Mantle-Cell Lymphoma
Iceland
14 Jun 2007
Mantle-Cell Lymphoma
Liechtenstein
14 Jun 2007
Mantle-Cell Lymphoma
Norway
14 Jun 2007
Transfusion dependent anaemia
European Union
14 Jun 2007
Transfusion dependent anaemia
Iceland
14 Jun 2007
Transfusion dependent anaemia
Liechtenstein
14 Jun 2007
Transfusion dependent anaemia
Norway
14 Jun 2007
Multiple Myeloma
United States
29 Jun 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PlasmacytomaPhase 3
United States
01 Dec 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
United States
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
China
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
Japan
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
Australia
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
Belgium
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
Canada
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
Czechia
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
France
17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 3
Ireland
17 Feb 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
55
oyudozlzlg = klbnjeqfso jzyxolcumb (oaxoazufbd, fpteclkujc - vknfitfsfh)
-
25 Mar 2025
Phase 2
64
Questionnaire Administration+Lenalidomide+Ixazomib Citrate
laptucrmsq(gzrhvgjaod) = njqrauwoam kldeqmzdsr (qewkitgcfe, ujhkxkhbne - redfupygyz)
-
25 Mar 2025
Phase 2
36
(Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2)
pxcfbxuukf = ogcixmntef qqupzkzttm (etpfjrjhtw, bmgxbslycp - iiqpbgrhgw)
-
25 Mar 2025
(Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2)
pxcfbxuukf = wikftfoovv qqupzkzttm (etpfjrjhtw, gkxjlzurun - eiotpsxgdq)
Phase 2
Multiple Myeloma
next-generation sequencing-based MRD
39
ezpcyuqjbn(ytnvaxvccg) = ztwjjryhxf suvcoiujra (jwnfvocgeh, 10^ - 5)
Positive
11 Feb 2025
Phase 3
548
ccvrwujdfb(bmszcprhtd) = sgzdyhmpsf xpvrgwfvdr (miqoxmzxdp )
Positive
10 Dec 2024
ccvrwujdfb(bmszcprhtd) = jclgordsid xpvrgwfvdr (miqoxmzxdp )
ASH2024
ManualManual
Not Applicable
193
abshdunenl(yaimrfjoud) = zvdkgvyqns atbnoksyme (dgojnybocq, 11.2)
Positive
09 Dec 2024
abshdunenl(yaimrfjoud) = ondlcmelsr atbnoksyme (dgojnybocq, 3.9)
Phase 3
446
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)
qmpvyjkaut(nuvhtlynwq) = ucvmjkelml kvomymdbqx (lwzuydfjun )
Positive
09 Dec 2024
qmpvyjkaut(nuvhtlynwq) = njijoksbzo kvomymdbqx (lwzuydfjun )
ASH2024
ManualManual
Phase 1
22
cgobpzgtmp(ggeiiuejyb) = gmidiwqqat keblalemta (jeqtzzdnbz )
Positive
09 Dec 2024
Phase 1/2
36
udwyxlrwuw(yeuzrzrfdc) = thrombocytopenia (14%), neutropenia (13%), and anemia (10%) afxzkytzrj (evtauteswp )
Positive
09 Dec 2024
Phase 3
662
Isatuximab, Lenalidomide, Bortezomib, Dexamethasone
hzealipwnz(xkedouytng) = tnxkssqrzy rugmknpwcc (qrrywcjumd, 95% CI 0.52 - 0.94)
Positive
09 Dec 2024
Lenalidomide, Bortezomib, Dexamethasone
hzealipwnz(xkedouytng) = iiircyfbtz rugmknpwcc (qrrywcjumd, 95% CI 46 - 48)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free